Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study-Reference-Cited by-同舟云学术

Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study

Published:2016-09 Issue:3 Volume:65 Page:524-531
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Belli Luca Saverio,Berenguer Marina,Cortesi Paolo Angelo,Strazzabosco Mario,Rockenschaub Susanne-Rasoul,Martini Silvia,Morelli Cristina,Donato Francesca,Volpes Riccardo,Pageaux Georges-Philippe,Coilly Audrey,Fagiuoli Stefano,Amaddeo Giuliana,Perricone Giovanni,Vinaixa Carmen,Berlakovich Gabriela,Facchetti Rita,Polak Wojciech,Muiesan Paolo,Duvoux Christophe

Publisher

Elsevier BV

Subject

Hepatology

Reference12 articles.

1. Ledipasvir and sofosbuvir plus ribavirin is patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial;Manns;Lancet Infect Dis,2016

2. Afdhal N, Everson GT, Calleja JL, McCaughan G, Bosch J, Denning J, et al. Effect of Long-Term Viral Suppression With Sofosbuvir + Ribavirin on Hepatic Venous Pressure Gradient in HCV-Infected Patients With Cirrhosis and Portal Hypertension.2015 International Liver Congress: 50th Annual Meeting of the European Association of the Study of the Liver (EASL) 2015; Abstract LP13.

3. Impact of direct antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis;Foster;J Hepatol,2016

4. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 study;Poordad;J Hepatol,2015

5. Jacobson IM, Poordad F, Firpi-Morell R, Everson GT, Verna EC, Bhanja S, et al. Efficay and safety of grazoprevir and elbasivir in hepatitis C genotype 1 infected patients with CP class B cirrhosis . (C-SALT PART A). 2015 International Liver Congress: 50th Annual Meeting of the European Association of the Study of the Liver (EASL) 2015; Abstract O 08.

Cited by 292 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recompensation after TIPS reduces the incidence of hepatocellular carcinoma and increases survival in patients with cirrhosis;Liver International;2024-09-02

2. EASL position paper on clinical follow-up after HCV cure;Journal of Hepatology;2024-08

3. Durability and on-treatment predictors of recompensation in entecavir-treated patients with hepatitis B and decompensated cirrhosis;JHEP Reports;2024-07

4. Recompensation of cirrhosis in candidates of transplant: Tips and tricks for delisting;Liver Transplantation;2024-05-28

5. Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C Infection and Decompensated Cirrhosis;Digestive Diseases and Sciences;2024-04-05